APP Pharmaceuticals, Praised For Easing Drug Shortages, Gets Manufacturing Warning Letter
This article was originally published in The Pink Sheet Daily
APP is singled out for helping alleviate the shortage of the cancer drug methotrexate at the same time the company’s manufacturing plant in Grand Island, N.Y. is cited for numerous cGMP violations.
You may also be interested in...
How contamination, sterility assurance, OOS and other issues caused drug recalls to spike again last year. What happened at Aidapak, H&P, Ben Venue, Hospira, Teva and other manufacturers to set a new record.
FDA press conference on alleviating shortages shows how the agency works with industry to advance legislation that firms may not be particularly fond of themselves. But the agency still seems to face an uphill legislative battle.
Rapid approval of a new, preservative-free generic methotrexate and permission to import an unapproved version of doxorubicin touted at press conference as FDA emphasizes the success of administrative efforts.